Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Zhenjiang Zheng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5100942736. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper

Papers 11

  1. The function of microRNA related to cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bcp.2025.116849↗
  2. Growth inhibition of pancreatic cancer by targeted delivery of gemcitabine via fucoidan-coated pH-sensitive liposomes. Co-author DOI 10.1016/j.ijbiomac.2024.134517↗
  3. Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma. First author DOI 10.1097/cad.0000000000001545↗
  4. Remnant Pancreas Volume Affects New-Onset Impaired Glucose Homeostasis Secondary to Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12081653↗
  5. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective… Co-author DOI 10.1002/cam4.5779↗
  6. Elevated Bile Acid Is Associated with Worsened Impaired Glucose Homeostasis in Pancreatic Ductal Adenocarcinoma Patients with Extrahepatic Cholestasis through … Co-author DOI 10.3390/jcm12062352↗
  7. Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis. Co-author DOI 10.4251/wjgo.v14.i10.1903↗
  8. Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study. Co-author DOI 10.1097/md.0000000000019327↗
  9. Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis. Co-author DOI 10.1186/s12893-019-0537-1↗
  10. Disparities in survival by stage after surgery between pancreatic head and body/tail in patients with nonmetastatic pancreatic cancer. Co-author DOI 10.1371/journal.pone.0226726↗
  11. Deleted in liver cancer-1 inhibits cell growth and tumorigenicity in human pancreatic cancer. Co-author DOI 10.3892/ol.2013.1415↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chunlu Tan · 11 shared papers, 2013–2025 · strength 1.87
  2. Yonghua Chen · 5 shared papers, 2019–2024 · strength 0.96
  3. Xubao Liu · 6 shared papers, 2013–2024 · strength 0.91
  4. Jie Yang · 2 shared papers, 2023–2024 · strength 0.48
  5. Yonghua Chen · 3 shared papers, 2019–2022 · strength 0.43
  6. Xing Wang · 2 shared papers, 2023 · strength 0.42
  7. Epiphane K. Silli · 2 shared papers, 2024–2025 · strength 0.38
  8. Xu-Bao Liu · 2 shared papers, 2020–2022 · strength 0.32
  9. Nengwen Ke · 2 shared papers, 2019–2023 · strength 0.32
  10. Xu-Bao Liu · 1 shared paper, 2024 · strength 0.26
  11. Yonghua Chen · 1 shared paper, 2023 · strength 0.22
  12. Yichen Li · 1 shared paper, 2024 · strength 0.22
  13. Xiaoding Shen · 1 shared paper, 2023 · strength 0.20
  14. Jia Chen · 1 shared paper, 2025 · strength 0.20
  15. Ying Wang · 1 shared paper, 2025 · strength 0.20
  16. Yaohui Fang · 1 shared paper, 2025 · strength 0.20
  17. Haoqi Zhang · 1 shared paper, 2022 · strength 0.19
  18. Jing Li · 1 shared paper, 2022 · strength 0.19
  19. Ying Wang · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.